跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 5,483 条关于
“ALK R1275Q”
全部
5,483
临床试验
4,140
药物
496
机构
76
资讯
771
去年
CHOP Researchers Propose ALK Inhibitors as New Standard for Hereditary Neuroblastoma
3年前
Lorlatinib Shows Promise in ALK-Driven Refractory Neuroblastoma with Emerging Resistance Mechanisms Identified
9年前
FDA Approves Fourth ALK Inhibitor for Lung Cancer
去年
Lorlatinib Shows Impressive 5-Year PFS Results in ALK-Positive Advanced NSCLC
去年
Gilteritinib Shows Promise as ALK Inhibitor in Acute Myeloid Leukemia
6个月前
TRIANA Biomedicines' TRI-611 Receives FDA Fast Track Designation for ALK+ NSCLC Treatment
去年
Alkeus' Gildeuretinol Receives FDA Rare Pediatric Disease and Fast Track Designations for Stargardt Disease
5年前
Lorlatinib Shows Promising Efficacy in ALK-Rearranged NSCLC with 21.8 Month Median PFS
去年
Ongoing Trials Explore Novel Combinations and Adjuvant Therapies in EGFR- and ALK-Mutant NSCLC
去年
ALK Partners with Gensci to Overcome Chinese Regulatory Challenges and Expand into Immunotherapy
第 1 页,共 78 页
上一页
下一页